The FDA Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling was published in April 2015. Since then questions have been raised regarding how to determine the relative abuse-deterrent (AD) effect of an AD formulation (a test product) compared to an immidiate release (IR) or NonAD extended release (ER) formulation of the same opioid (a positive control) and how to define a responder for responder analysis in clinical abuse potential studies. These questions are reasonable and important for the assessment of AD effect of an AD formulation. This article discusses the principles of the statistical assessment in this area and gives details on how to calculate sample size for the primary comparison in the study and how to perform the statistical analyses. In addition, the article also discusses the reason why the non-inferiority test is not proper for the comparison between a test product and an approved AD version of the same opioid product. Finally, a gatekeeping testing procedure is proposed for this comparison with an example.
Introduction
The abuse of and addiction to opioids is a serious and challenging public health problem. Deaths from drug overdose have risen steadily over the past 2 decades and have become the leading cause of injury death in the United States. 1 Prescription drugs, especially opioid analgesics-a class of prescription drugs such as hydrocodone, oxycodone, morphine, and methadone used to treat both acute and chronic pain-have increasingly been implicated in drug overdose deaths over the last decade. [2] [3] [4] One means of addressing the problem of prescription opioid abuse and overdose is the development of abuse-deterrent opioid products.
In April 2015, FDA published the final FDA Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling. 5 The Guidance recommends 3 categories of the premarketing evaluation of AD opioid products: Laboratory Manipulation and Extraction Studies (Category 1), Pharmacokinetic Studies (Category 2), and Clinical Abuse Potential Studies (Category 3). These studies are intended to be predictive of the likelihood that the AD product will deter or reduce in abuse of the product through the oral, intranasal, or intravenous routes; however, the relationship between the results of these studies and actual effects on abuse has yet to be determined. 6 Clinical abuse potential studies used to assess AD products generally use a randomized, double-blind, placebo-and positive comparator-controlled crossover design. Subjects in the clinical abuse potential study are opioid-experienced nondependent subjects who have experience with the particular route of abuse being studied.
The primary measure of the study is drug liking on a bipolar visual analog scale (Drug Liking VAS) from 0 to 100 mm. The 0, 50, and 100 on the scale denote strongly disliking, neither like nor dislike, and strongly liking, respectively. This is an "atthe-moment" measure. The question "Do you like the drug effect you are feeling now?" is asked for subject responses at multiple time points after a single dose administration. Drug Liking Emax is the primary endpoint of the study, which is the maximum response in drug liking within a given period of time. Detailed requirements for the study design can be found in the FDA 2015 Guidance.
The statistical analyses on the primary endpoint recommended in the FDA 2015 Guidance are described below.
Let C, T, and P denote the positive control (IR or NonAD ER opioid product), test product (proposed AD product), and placebo, respectively. The Guidance recommends testing the following hypotheses in the primary and secondary analyses in the clinical abuse potential study for bipolar Drug Liking Emax.
The primary hypothesis is
; m C and m T denote the means of positive control and test product, respectively.
Note that Drug Liking VAS is on a bipolar scale; 50 is a neutral score; scores less than 50 represent disliking, and scores greater than 50 represent liking. Both T and C are opioid products. The means of maximum liking for both treatments are expected greater than 50, and m C À m T ¼ ðm C À 50Þ À ðm T À 50Þ. Therefore, for comparability, 50 must be subtracted from m C on the right-hand side of the inequality in the hypothesis.
The test result from (1) needs to be validated by the comparison between the positive control and placebo as follows:
where m P denotes the mean of placebo.
The clinical abuse potential study has an enrichment design. After the screening phase, subjects will be enrolled to a prequalification phase (or called qualification phase). In the prequalification phase, subjects take the positive control and placebo (crossover). One of the selection criteria for a qualified subject is as follows: a greater than or equal to 15-point difference in maximum liking between positive control and placebo during the first 2 hours following drug administration. Therefore, a test value of 15 is required for the validation test.
The hypothesis in the responder analysis (one of the recommended secondary analyses) is
where p Ã denotes the percentage of responders. A responder is defined as a subject who had at least d Ã 100% of reduction in Drug Liking Emax for the test product relative to the positive control. The purpose of this test is to examine if majority subjects are responders. All 3 tests are 1-sided tests, and a, the nominated type I error rate, is 0.025.
The FDA 2015 Guidance recommends sponsors prespecifying d Ã in the protocol. The d Ã is also needed for the sample size determination.
The second section of this article discusses the importance of the above hypotheses, and how to perform the tests for these hypotheses. A gatekeeping testing procedure 7 for the comparison between a test product and an approved AD product is proposed in the third section with an example. The fourth section contains concluding remarks.
Testing Hypothesis for the AD Effect Hypotheses
Define the relative AD effect on maximum liking for a test product compared to its positive control as follows:
The y is the ratio of the mean difference between the positive control and the test product to the mean of the positive control on the bipolar scale of liking. Note that the mean of the positive control, m C , is greater than 50 on Drug Liking VAS. Thus, the primary hypothesis in (1) is equivalent to
If the test result is statistically significant, one may conclude that the test product has a larger than d*100% reduction in mean of maximum liking compared to the positive control. The FDA 2015 Guidance also recommends the use of 95% confidence interval for m C À m T . This confidence interval can provide the information about the absolute difference in means between 2 treatments on maximum liking.
When the result from the test for the hypothesis in (1) is statistically significant and indicates that test product has a larger than d Ã 100% reduction in mean compared to positive control; naturally, one would like to know what percent reduction the majority of subjects have. This leads to the responder analysis for testing the null hypothesis in (3).
Without specifying the d Ã in the primary hypothesis, the primary analysis cannot be done. Without a clear definition for a responder, the responder rate cannot be calculated, and hence the responder analysis cannot be performed.
About the Unknown d

Ã
The d
Ã plays a critical role in the statistical analysis. It is the test value of the hypothesis in (5), and should be clinically meaningful and prespecified in the protocol.
One may construct a 1-sided 97.5% confidence interval of y in (4) , and compare the lower confidence limit (LCL) of y to the prespecified d Ã : If the LCL is greater than d Ã , then the test for the null hypothesis in (5) is statistically significant. Actually, the LCL À e, where e > 0; is an approximation of the largest d Ã that the test would be statistically significant.
To avoid finding the sampling distribution of the test statistic for the hypothesis in (5), one may rewrite the hypothesis in (1) as follows:
The left-hand side of the inequality in the hypothesis is a linear combination of 2 treatment means. The test can start with the prespecified and clinically meaningful d Ã : If the result from the test for H 0 in (6) is statistically significant, then test the null with a 0.05 increment on d Ã until an insignificant result is obtained. By using this closed testing procedure, 8 one may obtain a larger d Ã than the prespecified one without inflating the type I error rate. One may refine d Ã to a 0.01 increment for the testing procedure. Note that the final d Ã is lower than but close to the 97.5% LCL of y in (4) . The closed testing procedure should be prespecified in the protocol.
Similarly, one may use a cutoff point d Ã 100% for a responder in the order from small percent to large percent with 5% increment to define a responder, and then test the null hypothesis in (3) ; that is, the majority subjects are not responders, until an insignificant result is obtained. The d Ã 100% also can be refined to a 1% increment in the testing procedure.
Recall that before the FDA 2015 Guidance published in this area, the primary hypothesis in a human drug abuse potential study was
By rejecting H 0 in (7), one can conclude that the test product has a smaller mean of maximum liking than the positive control. However, by rejecting H 0 in (6), one can conclude that the test product has a greater than d Ã 100% reduction in mean of maximum liking compared to the positive control. Because 0 < d Ã < 1 and m C > 50; the right-hand side of the hypothesis in (1) is greater than zero. Therefore, by rejecting H 0 in (1) (or in (6)) implies rejecting H 0 in (7), but the reverse is not true. In the past by testing the hypothesis in (7), sometimes one may obtain a statistically significant result with a very small and clinically nonmeaningful difference in means between 2 treatments. By testing H 0 in (1) one can obtain informative results, and can quantify the relative AD effect of a test product compared to a positive control.
Sample Size Determination
The sample size determination must take the primary objective of the study into account. There have been proposals to calculate the sample size for the primary comparison between the test product and the positive control in the clinical abuse potential study as follow:
Propose a d Ã , and find a historical sample mean of the positive controlm C . Calculated 1 ¼ d Ã ðm C À 50Þ, and then treatd 1 as a constant to calculate the sample size for the following hypothesis:
The hypothesis in (8) is not equivalent to the hypothesis in (1) recommended in the FDA 2015 Guidance. The proposed method will overestimate the sample size for the study. Below is a listing of the information that may be used for the sample size calculation for testing the hypothesis in (6): The information related to C can be obtained from historical data. The information related to T can be estimated based on the sponsor's understanding of the test product. Given a d Ã , the sample size calculation for testing the null hypothesis in (6) is based on a 1-sided paired t test. However, if a closed testing procedure is used, the sample size calculation should take the closed testing procedure into consideration. For instance, suppose the prespecified d Ã is 0.1. Based on information of the test product in hand, the sponsor knows that the test product can do much better than 10% reduction in the mean of maximum liking compared to the positive control, say 50% reduction. If budget allows, the test for the null hypothesis in (6) should be powered for d Ã ¼ 0.5 instead of 0.1. The following is an example. Table 1 provides summary statistics for the mean and standard deviation for the positive control and test product, as well as Pearson correlation coefficient between the positive control and test product for Drug Liking Emax in 3 studies. The N is the actual sample size used to calculate these estimates. To masking the studies, the data have been slightly modified. Ã , the sample sizes 33, 71, and 6 are needed for the test in studies 1, 2, and 3, respectively. From the graph, one may see that if choosing a sample size of 34 for study 3, the test may demonstrate greater than 60% reduction in mean of maximum liking for the test product compared to the positive control with a power of at least 90%. Note that the larger final d Ã , the larger relative AD effect on liking of the test product compared to the positive control. The closed testing procedure gives the opportunity to find the larger d Ã than prespecified one. Thus, the sample size calculation for this test should take the closed testing procedure into account. In fact, the sample size used in study 3 was 28.
Comparison Between a Proposed AD Product and an Approved AD Version of the Same Opioid Product
A Gatekeeping Testing Procedure
In April 2015 the FDA issued the final Guidance for Industry to assist pharmaceutical companies in developing drug products with AD properties. Since 2010, several opioids with AD formulation technology have been approved by the FDA, and more are in development. The question has been raised regarding how to compare a proposed AD product to an approved AD The usual reason for using an NI active control study design instead of a superiority design is an ethical one. Specifically, this design is chosen when it would not be ethical to use a placebo, or a no-treatment control, or a very low dose of an active drug, because there is an effective treatment that provides an important benefit (e.g., life-saving or preventing irreversible injury) available to patients for the condition to be studied in the trial.
In clinical abuse potential studies for AD products, the assessment of AD properties of a test product is based on the superiority test between the test product and an IR or NonAD ER opioid product (positive control). The positive control in clinical abuse potential studies plays a similar role to a placebo, or a nontreatment control, or a very low dose of an active drug in general efficacy studies. That is, for showing drug efficacy (proposed indication of the test product), the test product needs to compare to a placebo, or a nontreatment control, or a very low dose of an active drug; and for showing AD effect of a test product (a product having efficacy for deterring or reducing abuse by selected routes of administration), the test product needs to compare to an IR or NonAD ER opioid product. The non-inferiority test is used in a general efficacy study when a placebo or a non-treatment control, or a very low dose of an active drug cannot be used in the study for ethical reason. However, when a second-generation AD product is proposed, the most informative clinical abuse potential study would include IR or NonAD ER opioid product as a positive control for the purpose of the study validation, even though an approved AD product may be included in the study. In such a case, the assessment of AD properties of a test product relies on the superiority test for the comparison between test product and IR or NonAD ER opioid product. If the comparison between the test product and an approved AD product is also of interest, a possible approach would be to use the gatekeeping testing procedure presented in Figure 2 . Figure 2 shows that the validation test is conducted first. The test result will provide the information whether or not study subjects respond to the positive control. If the validation test fails, the study fails. If the validation test passes, one may do the comparison between the test product and the positive control. The test result will show if the test product is an AD product. If yes, do the comparison between the approved AD product and the positive control. The test result will provide information as to whether the approved AD product preserves some or all its AD properties on Drug Liking Emax in this study. If the test is not statistically significant, the comparison between the test product and the approved AD product is not meaningful. If the test is statistically significant, by comparing d
, and the results from other categories of assessments, a conclusion may be drawn on the test product, that is, if the test product is similar to the approved AD product in terms of AD properties. If a claim is that the test product has better AD properties than the approved AD product, the further comparison between the test product and the approved AD product is needed even if d
Because there is an IR or NonAD ER opioid product in the study, one can assess the AD effect of the test product directly using a superiority test. Whether the test product is a better AD product than the approved AD product is based on totality of data from all studies on this product and clinical judgment.
An Example
For demonstrating the gatekeeping testing procedure proposed in the above section, data from 2 clinical abuse potential intranasal studies were combined. The sample size and the data were modified to mask these studies. Table 2 summarizes the mean, standard deviation (SD), minimum (Min), the first quartile (Q1), median, the third quartile (Q3), and maximum (Max) for the treatments in the study for Drug Liking Emax.
The statistical model used in the primary analysis was a linear mixed-effects model that included period, sequence, and treatment as fixed effects and subject as a random effect. The model assumption for homogeneity of variance was examined using Levene test. The result of the Levene test was statistically significant (P ¼ .0001). Therefore, the heteroskedasticity was adjusted in the model. The model assumption of the normality of error teams was also examined using Shapiro-Wilk W test on the residuals. The test was not statistically significant with a P-value of .0773. Table 3 shows the least square mean (LSmean), standard error (SE), and the lower and upper limits of the 95% confidence interval (LCL and UCL) of mean for each treatment for Drug Liking Emax.
Following the gatekeeping testing procedure proposed in Figure 2 , the comparison between the positive control and placebo was done first. Because there was no prespecified d Abbreviations: AD, approved AD product; C, positive control; CI, confidence interval; LCL, lower confidence limit; P, placebo; SE, standard error; T, test product; UCL, upper confidence limit.
T and C, and between AD and C. The testing results show the following:
1. The difference in means of maximum liking between the positive control and placebo was statistically significantly greater than 15 (P < .0001). 2. The test product had statistically significantly larger than 37% reduction in mean of maximum liking compared to the positive control (P ¼ .0222). 3. The approved AD product had statistically significantly larger than 11% reduction in mean of maximum liking compared to the positive control (P ¼ .0210).
However, when comparing the test product to the approved AD product, even if setting d Ã 3 ¼ 0, the test result was not statistically significant (P ¼ .0422). Table 4 lists the test value or d Ã ; the estimate of the linear combination of m C and m T in the left-hand side of the inequality of the null hypothesis; the standard error of the estimation (SE); the P value of 1-sided t test; and the lower and upper limits of the 95% confidence interval (LCL and UCL) of the mean difference between 2 treatments for Drug Liking Emax.
From Table 4 , one may see that the test product, compared to the positive control, had 26% more percent reduction in mean of maximum liking than the approved AD product. However, the direct comparison between these treatments did not show the significant mean difference even with a test value zero.
Concluding Remarks
The clinical abuse potential study is an important part of the assessment of AD opioids. The d Ã in the primary hypothesis is the test value for the relative AD effect of the test product compared to the positive control, y. It should be clinically meaningful and prespecified in the protocol. One may use a closed testing procedure to obtain a larger d Ã than the prespecified one. However, the closed testing procedure should be prespecified, and taken into consideration in the sample size determination.
It is not proper to use a non-inferiority test for the comparison between a test product and an approved AD product. Because an IR or NonAD ER opioid product is in the study, one can compare the test product to an IR or NonAD ER opioid product directly using a superiority test as the primary assessment of the product. If the comparison between test product and an approved AD product is also one of the primary objectives, a gatekeeping testing procedure is proposed in Figure 2 .
The hypotheses and testing procedures discussed in this article are not restricted to Drug Liking VAS. They could be extended to other abuse potential measures. Abbreviations: AD, approved AD product; C, positive control; CI, confidence interval; P, placebo; SE, standard error; T, test product. *Estimate of the left-hand side of the inequality in the null hypothesis.
